California Cancer Reporting System Standards Volume I: Abstracting and Coding Procedures for Hospitals
Due to ongoing studies, the CCR is continuing to require that borderline ovarian tumors be reported for cases diagnosed January 1, 2010 and forward.
Recording Collaborative Staging data items will be simplified using the coding guidelines provided below that were developed with the assistance of the CCR's Cancer Epidemiology and Research Unit and regional registries.
In addition, active follow-up will no longer
be required for cases diagnosed January 1, 2001 and forward. Follow-up
will be obtained through passive follow-up linkages performed at the
CCR. Reporting facilities may elect to continue conducting active
follow-up on these cases. These cases will only be visually
edited for failed electronic edits.
2010 Coding Guidelines |
CSv2 Suggested Codes* |
CS Extension |
999 |
CS Tumor Size /Extension Eval |
9 |
CS Lymph Nodes |
999 |
CS Lymph Nodes Eval |
9 |
Regional Lymph Nodes Positive |
99 |
Regional Lymph Nodes Examined |
99 |
CS Mets |
99 |
CS Mets at DX - Bone |
9 |
CS Mets at DX - Brain |
9 |
CS Mets at DX - Liver |
9 |
CS Mets at DX - Lung |
9 |
CS Mets Eval |
9 |
* Registrars may choose to include a value other than the suggested codes in any of the fields.
CS Tumor Size: Continue to code tumor size as directed in the Collaborative Stage (CS) Data Collection System
SSF 1-SSF 5: 999
SSF 6 - SSF 25: 988
Class of Case: 34, 36 (using the 2010 revised codes)
Although borderline ovarian tumors changed behavior in ICD-O-3 from /3 (malignant) to /1 (borderline), the CCR will continue to require reporting them. They are to be coded with a behavior code of /1.
As listed in Appendix 6 of the ICD-O-3 Code Manual, reportable borderline ovarian tumors include the following terms and morphology codes:
Description |
Code |
Serous cystadenoma, borderline malignancy |
8442/1 |
Serous tumor, NOS, of low malignant potential |
8442/1 |
Papillary cystadenoma, borderline malignancy |
8451/1 |
Serous papillary cystic tumor of borderline malignancy |
8462/1 |
Papillary serous cystadenoma, borderline malignancy |
8462/1 |
Papillary serous tumor of low malignant potential |
8462/1 |
Atypical proliferative papillary serous tumor |
8462/1 |
Serous surface papillary tumor of borderline malignancy |
8463/1 |
Mucinous cystic tumor of borderline malignancy |
8472/1 |
Mucinous cystadenoma, borderline malignancy |
8472/1 |
Pseudomucinous cystadenoma, borderline malignancy |
8472/1 |
Mucinous tumor, NOS, of low malignant potential |
8472/1 |
Papillary mucinous cystadenoma, borderline malignancy |
8473/1 |
Papillary pseudomucinous cystadenoma, borderline malignancy |
8473/1 |
Papillary mucinous tumor of low malignant potential |
8473/1 |
Beginning with the implementation of Collaborative Staging, Version 01.04.00, and for borderline ovarian cases diagnosed on or after January 1, 2008, code CS Extension to 99.
Apply the Collaborative Staging ovary scheme for cases diagnosed on or after January 1, 2004. Do not use Collaborative Staging Extension code 00 (in situ) for borderline ovarian tumors. Follow-up is required for these cases.
For cases diagnosed prior to January 1, 2004, these cases are to be staged according to the ovary scheme in the EOD Manual.